Tonix director granted 22,700 stock options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Tonix Pharmaceuticals Holding Corp. director David L. Grange received a grant of stock options covering 22,700 shares of common stock. The options have an exercise price of $13.28 per share, vest on the earlier of one year from grant or the 2027 annual stockholders meeting, and expire in 2036.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 22,700 | $0.00 | $0.00 |
Footnotes (1)
- F1. The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan, and vests on the earlier of the one year anniversary of the grant date and the Issuer's 2027 Annual Meeting of Stockholders.
Key Figures
Key Terms
Stock Option financial
2026 Stock Incentive Plan financial
Annual Meeting of Stockholders financial
Grant, award, or other acquisition financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Tonix (TNXP) report for David L. Grange?
What is the exercise price of the new Tonix (TNXP) stock options?
When do David L. Grange’s Tonix (TNXP) options vest?
When do the newly granted Tonix (TNXP) stock options expire?
Under which plan were the Tonix (TNXP) options to David L. Grange granted?
How many Tonix (TNXP) derivative securities does David L. Grange hold after this grant?
AI-generated analysis. How Rhea-AI works. Not financial advice.